Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWHD-TAC7 is a proteolysis-targeting chimera (PROTAC) composed of a class I histone deacetylase (HDAC) inhibitor linked to the cereblon ligand pomalidomide (Item No. 19877).1 It binds to HDAC1, HDAC2, and HDAC3 (IC50s = 3.6, 4.2, and 1.1 µM, respectively) and induces degradation of HDAC3 in RAW 264.7 cells with a half-maximal degradation concentration (DC50) value of 0.32 µM, without inducing degradation of HDAC1 or HDAC2. HD-TAC7 (10 µM) increases acetylation of histone H3 lysine 27 (H3K27Ac) in RAW 264.7 macrophages but reduces the levels of NF-κB p65 and does not increase the expression of IL10 in LPS- and IFN-γ-stimulated RAW 264.7 macrophages, effects attributed to the pomalidomide moiety.
WARNING This product is not for human or veterinary use.